203 related articles for article (PubMed ID: 33997102)
21. Renal proximal tubular cells acquire resistance to cell death stimuli in mice with hereditary tyrosinemia type 1.
Luijerink MC; van Beurden EA; Malingré HE; Jacobs SM; Grompe M; Klomp LW; Berger R; van den Berg IE
Kidney Int; 2004 Sep; 66(3):990-1000. PubMed ID: 15327392
[TBL] [Abstract][Full Text] [Related]
22. Iron overload in hereditary tyrosinemia type 1 induces liver injury through the Sp1/Tfr2/hepcidin axis.
Bao WD; Fan Y; Deng YZ; Long LY; Wang JJ; Guan DX; Qian ZY; An P; Feng YY; He ZY; Wang XF; Phillip Koeffler H; Hu R; Wang J; Wang X; Wang F; Li JJ; Xie D
J Hepatol; 2016 Jul; 65(1):137-145. PubMed ID: 27013087
[TBL] [Abstract][Full Text] [Related]
23. Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I.
Overturf K; al-Dhalimy M; Ou CN; Finegold M; Tanguay R; Lieber A; Kay M; Grompe M
Hum Gene Ther; 1997 Mar; 8(5):513-21. PubMed ID: 9095403
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic Targeting of Fumaryl Acetoacetate Hydrolase in Hereditary Tyrosinemia Type I.
Gil-Martínez J; Macias I; Unione L; Bernardo-Seisdedos G; Lopitz-Otsoa F; Fernandez-Ramos D; Lain A; Sanz-Parra A; Mato JM; Millet O
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670179
[TBL] [Abstract][Full Text] [Related]
25. Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development.
Marhenke S; Lamlé J; Buitrago-Molina LE; Cañón JM; Geffers R; Finegold M; Sporn M; Yamamoto M; Manns MP; Grompe M; Vogel A
Hepatology; 2008 Aug; 48(2):487-96. PubMed ID: 18666252
[TBL] [Abstract][Full Text] [Related]
26. Kidneys of mice with hereditary tyrosinemia type I are extremely sensitive to cytotoxicity.
Jacobs SM; van Beurden DH; Klomp LW; Berger R; van den Berg IE
Pediatr Res; 2006 Mar; 59(3):365-70. PubMed ID: 16492973
[TBL] [Abstract][Full Text] [Related]
27. Mutational spectrum of Mexican patients with tyrosinemia type 1: In silico modeling and predicted pathogenic effect of a novel missense FAH variant.
Ibarra-González I; Fernández-Lainez C; Alcántara-Ortigoza MA; González-Del Angel A; Fernández-Henández L; Guillén-López S; Belmont-Martínez L; López-Mejía L; Varela-Fascinetto G; Vela-Amieva M
Mol Genet Genomic Med; 2019 Dec; 7(12):e937. PubMed ID: 31568711
[TBL] [Abstract][Full Text] [Related]
28. Mildly elevated succinylacetone and normal liver function in compound heterozygotes with pathogenic and pseudodeficient
Yang H; Rossignol F; Cyr D; Laframboise R; Wang SP; Soucy JF; Berthier MT; Giguère Y; Waters PJ; Mitchell GA;
Mol Genet Metab Rep; 2018 Mar; 14():55-58. PubMed ID: 29326876
[TBL] [Abstract][Full Text] [Related]
29. Mutations in the 4-hydroxyphenylpyruvic acid dioxygenase gene are responsible for tyrosinemia type III and hawkinsinuria.
Tomoeda K; Awata H; Matsuura T; Matsuda I; Ploechl E; Milovac T; Boneh A; Scott CR; Danks DM; Endo F
Mol Genet Metab; 2000 Nov; 71(3):506-10. PubMed ID: 11073718
[TBL] [Abstract][Full Text] [Related]
30.
Nicolas CT; Kaiser RA; Hickey RD; Allen KL; Du Z; VanLith CJ; Guthman RM; Amiot B; Suksanpaisan L; Han B; Francipane MG; Cheikhi A; Jiang H; Bansal A; Pandey MK; Garg I; Lowe V; Bhagwate A; O'Brien D; Kocher JA; DeGrado TR; Nyberg SL; Lagasse E; Lillegard JB
Mol Ther Methods Clin Dev; 2020 Sep; 18():738-750. PubMed ID: 32913881
[TBL] [Abstract][Full Text] [Related]
31. Direct sequencing of FAH gene in Pakistani tyrosinemia type 1 families reveals a novel mutation.
Ijaz S; Zahoor MY; Imran M; Afzal S; Bhinder MA; Ullah I; Cheema HA; Ramzan K; Shehzad W
J Pediatr Endocrinol Metab; 2016 Mar; 29(3):327-32. PubMed ID: 26565546
[TBL] [Abstract][Full Text] [Related]
32. Generation of immunodeficient pig with hereditary tyrosinemia type 1 and their preliminary application for humanized liver.
Ren J; Yu D; Wang J; Xu K; Xu Y; Sun R; An P; Li C; Feng G; Zhang Y; Dai X; Zhao H; Wang Z; Han Z; Zhu H; Ding Y; You X; Liu X; Wu M; Luo L; Li Z; Yang YG; Hu Z; Wei HJ; Ge L; Hai T; Li W
Cell Biosci; 2022 Mar; 12(1):26. PubMed ID: 35255981
[TBL] [Abstract][Full Text] [Related]
33. Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient.
Phaneuf D; Lambert M; Laframboise R; Mitchell G; Lettre F; Tanguay RM
J Clin Invest; 1992 Oct; 90(4):1185-92. PubMed ID: 1401056
[TBL] [Abstract][Full Text] [Related]
34. A case report of two siblings with hypertyrosinemia type 1 presenting with hepatic disease with different onset time and severity.
Kawabata K; Kido J; Yoshida T; Matsumoto S; Nakamura K
Mol Genet Metab Rep; 2022 Sep; 32():100892. PubMed ID: 35800472
[TBL] [Abstract][Full Text] [Related]
35. Abnormal social behavior in mice with tyrosinemia type I is associated with an increase of myelin in the cerebral cortex.
Moore ME; Koenig AE; Hillgartner MA; Otap CC; Barnby E; MacGregor GG
Metab Brain Dis; 2017 Dec; 32(6):1829-1841. PubMed ID: 28712060
[TBL] [Abstract][Full Text] [Related]
36. Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1.
Angileri F; Bergeron A; Morrow G; Lettre F; Gray G; Hutchin T; Ball S; Tanguay RM
JIMD Rep; 2015; 19():43-58. PubMed ID: 25681080
[TBL] [Abstract][Full Text] [Related]
37. Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I).
Tanguay RM; Valet JP; Lescault A; Duband JL; Laberge C; Lettre F; Plante M
Am J Hum Genet; 1990 Aug; 47(2):308-16. PubMed ID: 2378356
[TBL] [Abstract][Full Text] [Related]
38. Rescue from neonatal death in the murine model of hereditary tyrosinemia by glutathione monoethylester and vitamin C treatment.
Langlois C; Jorquera R; Orejuela D; Bergeron A; Finegold MJ; Rhead WJ; Tanguay RM
Mol Genet Metab; 2008 Mar; 93(3):306-13. PubMed ID: 18023223
[TBL] [Abstract][Full Text] [Related]
39. Tissue-specific FAH deficiency alters sleep-wake patterns and results in chronic tyrosinemia in mice.
Yang S; Siepka SM; Cox KH; Kumar V; de Groot M; Chelliah Y; Chen J; Tu B; Takahashi JS
Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22229-22236. PubMed ID: 31611405
[TBL] [Abstract][Full Text] [Related]
40. Functional analysis and in vitro correction of splicing FAH mutations causing tyrosinemia type I.
Pérez-Carro R; Sánchez-Alcudia R; Pérez B; Navarrete R; Pérez-Cerdá C; Ugarte M; Desviat LR
Clin Genet; 2014 Aug; 86(2):167-71. PubMed ID: 23895425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
